In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: Mobileye vets launch start-up to assess what drugs should go to trial
Mobileye vets launch start-up to assess what drugs should go to trial
The Jerusalem Post
OMEC.AI, founded by Ori Shachar and Amir Harel, aims to transform the process of drug discovery and development for the betterment of human health.
Visit: AION Labs Launches AI Startup Addressing Drug Trial Improvement
AION Labs Launches AI Startup Addressing Drug Trial Improvement
Mobile Health Times
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X OMEC.AI will use advanced machine learning to improve probability of success for drug candidates in clinical trials.
Visit: BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
PharmiWeb
Research team âEDCâ will study âExtrachromosomal DNA in Cancerâ. With this project, the two partners launch their ninth collaboration, seven of which have been in the field of oncology.
Visit: BioMedX Initiates New Oncology Research Project with Merck
BioMedX Initiates New Oncology Research Project with Merck
Contract Pharma
BioMed X, a German independent research institute, has started its new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation and function.
Visit: Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Medical Dialogues
Germany. BioMed X, a German independent research institute, has announced the start of its new research project titled ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany.
Visit: BioMed X Institute Enters New Collaboration with Merck
BioMed X Institute Enters New Collaboration with Merck
The Pharma Letter
German independent research institute BioMed X has announced the start of its new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Germanyâs Merck KGaA, Darmstadt. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation…
Visit: BioMed X Institute and Merck Start New Oncology Research Project
BioMed X Institute and Merck Start New Oncology Research Project
Labiotech.eu
BioMed X, a German independent research institute, has started a new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of ecDNA formation and function.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
Mobile Health Times
AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: âPrediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populationsâ.
Visit: Global Call for Scientists and Inventors to Form New Startup
Global Call for Scientists and Inventors to Form New Startup
Labiotech.eu
AION Labs and German independent research institute BioMed X, announced today (June 29) the launch of the fourth global call for application to identify biomedical scientists and inventors to form a new startup in Israel. This fourth startup will focus on the development of an AI platform that optimizes the patient population for phase 3 clinical trial oncology studies.
Visit: BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
#ScienceForUkraine
The BioMed X Institute, an independent research institute located in Heidelberg, Germany, is offering PhD positions in the field of Life Sciences (including pharmacology, bio-organic chemistry and physics) to early-career scientists from Ukraine.
Visit: BioMed X Institute Launches Ukraine Refugee Funding Program
BioMed X Institute Launches Ukraine Refugee Funding Program
Lab Manager
The program addresses early-career scientists (either master-level scientists or doctoral students) in the field of life sciences who cannot continue their research at their Ukrainian institutions.
Visit: Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Health Policy Watch
Together with its German partner BioMed X, AION Labs hosted 15 teams of computational biologists, AI researchers and biomedical scientists for a âboot campâ that aims to speed up the drug discovery process and lower costs â harnessing AI technologies in novel ways.
Visit: Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
LABMATE Online
A German independent research institute, BioMed X, announces today the start of its new research project âRegulatory T Cell Dysfunction in Autoimmunity and Inflammagingâ (TDA) in collaboration with Merck KGaA, Darmstadt, Germany.
Visit: BioMed X Institute and Merck KGaA Start Second Research Project in Immunology
BioMed X Institute and Merck KGaA Start Second Research Project in Immunology
PharmTech
BioMed X and Merck KGaA, Darmstadt, Germany announced their collaboration on a research project to study T-cells and autoimmunity.
Visit: BioMed X Initiates New Research Project in Collaboration with Merck
BioMed X Initiates New Research Project in Collaboration with Merck
Contract Pharma
Research team will examine âRegulatory T Cell Dysfunction in Autoimmunity and Inflammaging.â
Visit: BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development
BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development
PharmiWeb
Research team âBDBâ to develop an advanced biosensor for pharmacological monitoring in the brain. Fifth joint reseach project of the partners since 2014
Visit: Brain Training: BioMed X Institute collaborates with Boehringer Ingelheim
Brain Training: BioMed X Institute collaborates with Boehringer Ingelheim
PharmaTimes
Sensor development project marks the fifth joint research effort between BioMed X with Boehringer Ingelheim
Visit: AION Labs: At the forefront of the pharmaceutical revolution
AION Labs: At the forefront of the pharmaceutical revolution
The Jerusalem Post
Four times a year, five teams of scientists are invited to Israel for a five-day intensive boot camp, during which they solve a challenge relevant to todayâs pharma industry.
Visit: Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
nocamels
Israeli-headquartered, AION Labs, and German independent research institute, BioMed X, this week announced their third global call for biomedical scientists and interested investors to apply for a new AION Labs startup in Rehovot focused on âAI-enabled design and optimization of antibodies for targeted therapiesâ.
Visit: AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of the third global call for application to identify biomedical scientists and inventors to form a new startup at AION Labsâ headquarters in Rehovot, Israel.
Visit: BioMed X institute and Merck KGaA extend cancer collaboration
BioMed X institute and Merck KGaA extend cancer collaboration
thepharmaletter
German independent research institute BioMed X says it has extended its collaboration with Merck KGaA, Darmstadt, Germany.